CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE

被引：1
|
作者：
Souza, P., V [1 ]
Zanini, F. E. [1 ]
Biglia, L., V [1 ]
Kim, H. S. [2 ]
Fahham, L. [2 ]
机构：
[1] Merck, Sao Paulo, Brazil
[2] SENSE Co, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2578
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN26
引用
收藏
页码：A875 / A875
页数：1
相关论文
共 50 条
  • [41] Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer
    Qin, Shukui
    Liu, Tianshu
    Xu, Jianming
    Li, Qi
    Cheng, Ying
    Zhang, Aimar
    Esser, Regina
    Chang, Helena
    Li, Jin
    FUTURE ONCOLOGY, 2023, 19 (15) : 1053 - 1061
  • [42] First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
    Shousheng Liu
    Chang Jiang
    Lin Yang
    Jinsheng Huang
    Roujun Peng
    Xiaopai Wang
    Wenzhuo He
    Long Bai
    Yixin Zhou
    Bei Zhang
    Liangping Xia
    Scientific Reports, 10
  • [43] Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Han, Yu Na
    Choi, Yeo Jin
    Rhie, Sandy Jeong
    HEALTHCARE, 2022, 10 (02)
  • [44] Controversies in the treatment of RAS wild-type metastatic colorectal cancer
    R. Vera
    M. Salgado
    M. J. Safont
    J. Gallego
    E. González
    E. Élez
    E. Aranda
    Clinical and Translational Oncology, 2021, 23 : 827 - 839
  • [45] Controversies in the treatment of RAS wild-type metastatic colorectal cancer
    Vera, R.
    Salgado, M.
    Safont, M. J.
    Gallego, J.
    Gonzalez, E.
    Elez, E.
    Aranda, E.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 827 - 839
  • [46] Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer.
    Lee, Victor H. F.
    Fang, Weijia
    Lam, Ka On
    Choi, Cheuk Wai
    Ng, Sherry C. Y.
    Ho, Patty P. Y.
    Ho, Garrett C. L.
    Cheng, Thomas K. C.
    Liu, Rico K. Y.
    Leung, To Wai
    Kwong, Dora Lai Wan
    Zheng, Shusen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
    Chan, Wing-Lok
    Lee, Victor Ho Fun
    Siu, Wai Kwan Steven
    Ho, Pui Ying Patty
    Liu, Rico King Yin
    Leung, To Wai
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (03) : 175 - 178
  • [48] Treatment Advances in Liver-Limited Metastatic Colorectal Cancer
    Alberts, Steven R.
    Poston, Graeme J.
    CLINICAL COLORECTAL CANCER, 2011, 10 (04) : 258 - 265
  • [49] Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study
    Granieri, Stefano
    Cotsoglou, Christian
    Bonomi, Alessandro
    Salvatore, Lisa
    Filippi, Roberto
    Nigro, Olga
    Gelsomino, Fabio
    Zurlo, Ina Valeria
    Depetris, Ilaria
    Giampieri, Riccardo
    Berardi, Rossana
    Morelli, Cristina
    De Tursi, Michele
    Roberto, Michela
    Gjoni, Elson
    Germini, Alessandro
    de Angelis, Nicola
    Memeo, Riccardo
    Facciorusso, Antonio
    Garrone, Ornella
    Ramai, Daryl
    Ghidini, Michele
    Parisi, Alessandro
    CANCERS, 2022, 14 (22)
  • [50] The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
    Ciliberto, Domenico
    Staropoli, Nicoletta
    Caglioti, Francesca
    Chiellino, Silvia
    Ierardi, Antonella
    Ingargiola, Rossana
    Botta, Cirino
    Arbitrio, Mariamena
    Correale, Pierpaolo
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 69 - 77
12345